This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
« Back
Page 1 of 1
Next »

Ariad Pharma: The Contrarian Long Thesis

By Jim Silverman

Iclusig may find use in other cancers and '113 is better than the market believes.

11:00AM 10/24/13

Cell Therapeutics: Addicted to Reverse Stock Splits

By Jim Silverman

Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.

10:00AM 04/18/13

Programmed Insider Buying? Yes, at Insmed and United Therapeutics

By Jim Silverman

Instead of selling stock whenever the wind blows, biotech execs should be buying.

08:00AM 01/24/13

Genta: 1998-2012

By Jim Silverman

The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.

07:00AM 10/25/12

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

By Jim Silverman

How best to invest in the next important clinical trial catalyst facing Celgene.

08:07AM 09/25/12

« Back
Page 1 of 1
Next »

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,099.13 -63.86 -0.35%
S&P 500 2,116.67 -6.81 -0.32%
NASDAQ 5,089.7260 -16.8670 -0.33%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs